Spear Bio
Company

Last deal

$45M

Amount

Series A

Stage

29.07.2024

Date

2

all rounds

$45M

Total amount

date founded

Financing round

General

About Company
Spear Bio detects ultrasensitive protein.

Industry

Sector :

Subsector :

founded date

01.01.2021

Company Type

For Profit

Last funding type

Series A

IPO status

Private

Description

Spear Bio, a biotech company founded in 2021 and based in Weston, Massachusetts, has developed ultrasensitive protein detection technology that offers significant benefits across the healthcare value chain. The technology allows for self-testing and telemedicine-based diagnostics that rely on the ability to quantify minuscule amounts of protein biomarkers from at-home collected samples. Clinicians can use this technology to detect ultrasensitive protein from small sample volumes that fit into existing workflows for sample collection, processing, and detection.
Contacts
Similar Companies
1000
UltraDx Bio

UltraDx Bio

UltraDx Bio specializes in high-sensitivity protein detection technology.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

total rounds

1

total raised

$13.74M
Maven Biotechnologies

Maven Biotechnologies

Maven Biotechnology develops real-time and label-free imaging technology for protein microarrays, cell-based assays and biomarker detection.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Health Diagnostics

Location

Pasadena, CA, USA

total rounds

1

total raised

$1.96M
Biospin

Biospin

Biospin provides a revolutionary microbial detection system for F&B, water, and pharmaceutical products.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care

Location

Singapore

total rounds

1
TargetDx Laboratory

TargetDx Laboratory

TargetDx Laboratory specializes in early-stage non-small cell lung cancer detection using protein biomarkers and proprietary algorithms.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Medical

Location

San Jose, CA, USA

Financials

Funding Rounds
2
2

Number of Funding Rounds

$45M

Money Raised

Their latest funding was raised on 29.07.2024. Their latest investor Bio-Techne. Their latest round Series A

Date 
Funding Round 
Investors 
Money Raised 
Lead 
Foresite Capital

Foresite Capital

Foresite Capital is a healthcare and life sciences investment firm with $2 billion under management.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Biotechnology, Health Care, Financial Services

Location

San Francisco, CA, USA

count Of Investments

123

count Of Exists

11
Bio-Techne

Bio-Techne

Bio-Techne empowers researchers with reagents, instruments, manufacturing, and testing services in Life Science and Clinical Diagnostics.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Financial Services, Manufacturing

Location

Minneapolis, MN, USA

count Of Investments

6

count Of Exists

2
CDH Investments

CDH Investments

CDH Investments is an international alternative asset fund manager with over $2.0 billion of committed capital under management.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Financial Services, Finance

Location

Kowloon City District, Hong Kong

count Of Investments

248

count Of Exists

13
Sequoia Capital China

Sequoia Capital China

Sequoia Capital China is a venture capital firm that invests in fintech companies at various stages of growth.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

Beijing, China

count Of Investments

1001

count Of Exists

30
Co-Investors
Investors
6
4

Number of lead investors

6

Number of investors

Investor 
Lead 
Round 
Partners 
Bio-Techne

Bio-Techne

Bio-Techne empowers researchers with reagents, instruments, manufacturing, and testing services in Life Science and Clinical Diagnostics.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Financial Services, Manufacturing

Location

Minneapolis, MN, USA

count Of Investments

6

count Of Exists

2
Kim Kelderman

Kim Kelderman

Kim Kelderman is the President of Diagnostics and Genomics of Bio-Techne. He previously worked at Guangzhou Life Technologies DaAn Diagnostics Co., Ltd. China as a Member Board Of Directors. Kim Kelderman attended Columbia Business School.

Yonghua Capital

Yonghua Capital

Yongyong Investment specializes in equity investment management through its subsidiary Shanghai Chung Hua Investment Management.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Financial Services, Finance, Venture Capital

Location

Shanghai, China

count Of Investments

136

count Of Exists

3
Foresite Capital

Foresite Capital

Foresite Capital is a healthcare and life sciences investment firm with $2 billion under management.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Biotechnology, Health Care, Financial Services

Location

San Francisco, CA, USA

count Of Investments

123

count Of Exists

11
Vikram Bajaj

Vikram Bajaj

Vik is a Managing Director at Foresite, evaluating and pursuing investments at the intersection of technology and life sciences, including in personalized and precision healthcare. Prior to joining Foresite Capital, Vik was the Chief Scientific Officer of GRAIL, a life sciences company working to detect cancer early when it can be cured, and remains on its Scientific Advisory Board. He is also the Co-Founder and former Chief Scientific Officer of Verily (formerly Google Life Sciences) and served as Chair of its Scientific Advisory Board. A former academic principal investigator, Vik retains appointments as Associate Professor (consulting) at the Stanford School of Medicine, and as an Affiliate Scientist of the Lawrence Berkeley National Laboratory and the University of California, Berkeley, for which he serves on the advisory board of the College of Chemistry. He is an advisor to the Department of Defense through the Defense Science Board’s Task Force on Biology. Vik's research interests lie at the interface of the physical sciences, engineering, and the life sciences. He and his collaborators have developed nanotechnology probes for the early detection and molecular imaging of disease, spectroscopic tools for imaging objects on the nanoscale, microfabricated and miniaturized analytical and imaging systems for point-of-care testing, methods and devices that dramatically enhance the sensitivity and specificity of MRI, and new tools for clinical bioinformatics and integrative systems biology. Aspects of this work have been commercialized through several startups. At GRAIL, Vik led laboratory and data science teams at the forefront of industrial cancer genomics and diagnostics development. He holds a Ph.D. in physical chemistry from the Massachusetts Institute of Technology. Vik’s scientific and engineering awards include the Anatole Abragam Prize (2012), the R&D 100 Award for the most promising commercialized technologies (2011 and 2013), and the Department of Energy's LBL Innovation Grant (2013). In 2011, he was named as a Visiting Professor of the Chinese Academy of Sciences.

current job

Foresite Labs
Foresite Labs

People

Employee Profiles
3
Feng Xuan

Feng Xuan

Co-Founder & Chief Technology Officer

Peng Yin

Peng Yin

Co-Founder, Director

Activity

Recent News
2
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range

month